New bradykinin analogues substituted in positions 7 and 8 with sterically restricted 1-aminocyclopentane-1-carboxylic acid

被引:13
作者
Labudda, Olga
Wierzba, Tomasz
Sobolewski, Dariusz
Kowalczyk, Wioleta
Sleszynska, Matgorzata
Gawinski, Lukasz
Plackova, Marketa
Slaninova, Jirina
Prahl, Adam
机构
[1] Univ Gdansk, Fac Chem, Dept Chem, PL-80952 Gdansk, Poland
[2] Med Acad Gdansk, Dept Physiol, PL-80211 Gdansk, Poland
[3] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Grp Peptide Biochem, CZ-16610 Prague, Czech Republic
关键词
bradykinin; B-2; antagonists; 1-aminocyclopentane; 1-carboxylic acid; rat blood pressure assay; in vitro rat uterotonic test;
D O I
10.1002/psc.812
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A sterically constrained non-coded amino acid, 1-aminocyclopentane-1-carboxylic acid (Ape), was introduced in position 7 or 8 of the bradykinin (BK) B-2 receptor antagonist, [D-Arg(0), Hyp(3), Thi(5.8), D-Phe(7)]BK, previously synthesized by Stewart's group. This modification is believed to reduce the flexibility of the peptides, thereby forcing the peptide backbone and side chains to adopt specific orientations. Ape substitution was combined with acylation of the N-terminus with 1-adamantaneacetic acid (Aaa). The activity of four new analogues was assayed in isolated rat uterus and in rat blood pressure tests. The results clearly demonstrated that the Ape residue inserted in position 7 led to a reduction of antagonistic properties in the rat uterus assay or even restored the agonism in the blood pressure test, whereas Ape at position 8 enhanced antagonistic potency in both the tests. In both cases, acylation of the N-terminus led to the enhancement of the antagonistic potency. On the basis of these findings, new potent and selective B-2 blockers might be designed. Copyright (c) 2006 European Peptide Society and John Wiley & Sons, Ltd.
引用
收藏
页码:775 / 779
页数:5
相关论文
共 28 条
[1]   Bradykinin induced mitogenesis of androgen independent prostate cancer cells [J].
Barki-Harrington, L ;
Daaka, Y .
JOURNAL OF UROLOGY, 2001, 165 (06) :2121-2125
[2]  
BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129
[3]   New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules [J].
Derdowska, I ;
Prahl, A ;
Neubert, K ;
Hartrodt, B ;
Kania, A ;
Dobrowolski, D ;
Melhem, S ;
Trzeciak, HI ;
Wierzba, T ;
Lammek, B .
JOURNAL OF PEPTIDE RESEARCH, 2001, 57 (01) :11-18
[4]  
FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511
[5]   A new class of bradykinin antagonists containing indanylglycine [J].
Gera, L ;
Stewart, JM .
IMMUNOPHARMACOLOGY, 1996, 33 (1-3) :174-177
[6]   CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF A HUMAN BRADYKININ (BK-2) RECEPTOR [J].
HESS, JF ;
BORKOWSKI, JA ;
YOUNG, GS ;
STRADER, CD ;
RANSOM, RW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 184 (01) :260-268
[7]  
HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x
[8]   A MODIFICATION OF THE METHOD OF DALE AND LAIDLAW FOR STANDARDIZATION OF POSTERIOR PITUITARY EXTRACT [J].
HOLTON, P .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1948, 3 (04) :328-334
[9]   Influence of 1-aminocyclohexane-1-carboxylic acid in position 2 or 3 of AVP and its analogues on their pharmacological properties [J].
Jastrzebska, B ;
Derdowska, I ;
Kowalczyk, W ;
Machova, A ;
Slaninová, J ;
Lammek, B .
JOURNAL OF PEPTIDE RESEARCH, 2003, 62 (02) :70-77
[10]   New bradykinin analogues modified in the C-terminal part with sterically restricted 1-aminocyclohexane-1-carboxylic acid [J].
Labudda-Dawidowska, O ;
Wierzba, TH ;
Prahl, A ;
Kowalczyk, W ;
Gawinski, L ;
Plackova, M ;
Slaninová, J ;
Lammek, B .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (25) :8055-8059